Previous 10 | Next 10 |
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Chembio Diagnostics, Inc. Launches Commercial Distribution of Third-Party COVID-19 Antigen Test” Chembio Diagnostics, Inc. (NYSE: CEMI) climbed over 13% in premark...
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Ther...
Support.com (NASDAQ:SPRT) +59%. Navios Maritime Acquisition NNA +47% on merger agreement with Navios Maritime Partners NeuroMetrix (NASDAQ:NURO) +30%. PainReform (NASDAQ:PRFX) +22%. Bill.com BILL +15% on Q4 earnings. TSR (NASDAQ:TSRI) +15%. Taoping (NASDA...
HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point...
3 High Volume Robinhood Penny Stocks to Watch Now Penny stocks with high volume can be a great indicator of where the most popular small-caps are. For those unfamiliar, volume is the number of shares bought or sold on a given trading day. Often, investors will use this metric as a way t...
The following slide deck was published by Chembio Diagnostics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Chembio Diagnostics, Inc. 2021 Q2 - Results - Earnings Call Presentation
Are These Biotech Penny Stocks Worth Watching Right Now? There’s a reason why biotech penny stocks have remained so popular among investors this year. And while Covid initially was the main cause for heightened investor interest, its lasting effect has helped to bring a slew of t...
Spectrum Pharmaceuticals SPPI -35% after FDA declines to approve ROLONTIS Dicerna Pharmaceuticals DRNA -28% slide despite pivotal nedosiran study hitting primary endpoint Zynga ZNGA -16% on Q2 earnings release Chembio Diagnostics CEMI -13% on Q2 earning...
HAUPPAUGE, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2...
BeyondSpring BYSI +336% Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type Wheeler Real Estate (NASDAQ:WHLR) +18%. Robinhood Market...
News, Short Squeeze, Breakout and More Instantly...
Chembio Diagnostics Inc. Company Name:
CEMI Stock Symbol:
NASDAQ Market:
Chembio Diagnostics Inc. Website:
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of ...
MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 ...
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 ...